Clinical Trial Update: HS-10502 Combination Treatment in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for HS-10502 in patients with advanced solid tumors, including recurrent ovarian cancer and HER2-negative breast cancers, curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Ovarian Cancer
• Prostate Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• HS-10502

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Recurrent Ovarian Cancer, HER2-negative | Phase 1 | Status: RECRUITING